Advertisement

Long-Term Tamoxifen Therapy: An Appropriate Chemosuppressive Treatment for Breast Cancer

  • V. Craig Jordan
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

Tamoxifen (Nolvadex®) is a non-steroidal antioestrogen and the first-line endocrine therapy for breast cancer [1–3]. The drug has proved to have efficacy as an adjuvant in node-positive disease [3,4] and increasing numbers of node-negative breast cancer patients are being treated with tamoxifen [5]. A remarkable feature of treatment with tamoxifen is the low incidence of side effects [1,3]. These clinical observations and the large body of evidence from the laboratory [6,7] have focussed clinical attention on long-term, or indefinite (treatment until relapse), adjuvant tamoxifen therapy [5,8–10].

Keywords

Breast Cancer Endometrial Cancer Endometrial Carcinoma Tamoxifen Therapy Adjuvant Tamoxifen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharm Ther 1984 (25):127–205CrossRefGoogle Scholar
  2. 2.
    Jordan VC (ed) Estrogen/Antiestrogen Action and Breast Cancer Therapy. University of Wisconsin Press, Madison 1986Google Scholar
  3. 3.
    Love RR: Tamoxifen therapy in primary breast cancer: biology, efficacy and side effects. J Clin Oncol 1989 (7):803–815PubMedGoogle Scholar
  4. 4.
    Early Breast Cancer Trialists’ Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988(319):1681–1692CrossRefGoogle Scholar
  5. 5.
    Fisher B, Costantino J, Redmond C et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 1989 (320):479–484PubMedCrossRefGoogle Scholar
  6. 6.
    Jordan VC: Laboratory studies to develop general principles for the treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat 1983 (3 Suppl):s73–s86PubMedCrossRefGoogle Scholar
  7. 7.
    Jordan VC: Long-term tamoxifen therapy for breast cancer. In: DeVita VT, Hellman S, Rosenberg S (eds) Important Advances in Oncology. Lippincott, Philadelphia 1989 pp 179–192Google Scholar
  8. 8.
    Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 1984 (4) :297–302PubMedCrossRefGoogle Scholar
  9. 9.
    Fisher B and other NSABP Investigators: Prolonging tamoxifen for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 1987 (106):649–654PubMedGoogle Scholar
  10. 10.
    Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC): Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987 (ii):171–175Google Scholar
  11. 11.
    Love RR, Mazess RB, Tormey DC et al: Bone mineral density in women with breast cancer treated for at least two years with tamoxifen. Breast Cancer Res Treat 1988(12):297–301PubMedCrossRefGoogle Scholar
  12. 12.
    Turken S, Siris E, Seldin E et al: Effects of tamoxifen on spinal bone density in women with breast cancer. JNCI 1989 (91):1086–1088Google Scholar
  13. 13.
    Bertelli G, Pronzata P, Amaroso D et al: Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988 (12):307–310PubMedCrossRefGoogle Scholar
  14. 14.
    Antunes CM, Stolley PD, Rosenhein NB et al: Endometrial cancer and estrogen use: report of a large case-control study. N Engl J Med 1979 (300):9–13PubMedCrossRefGoogle Scholar
  15. 15.
    Weiss NS, Szekely DR, Austin DF: Increasing incidence of endometrial cancer in the United States. N Engl J Med 1976 (294):1259–1262PubMedCrossRefGoogle Scholar
  16. 16.
    Fox H: Endometrial carcinogenesis and its relation to ©estrogens. Path Res Pract 1984 (1979):13–19CrossRefGoogle Scholar
  17. 17.
    Whithead Ml, Fraser D: Controversies concerning the safety of estrogen replacement therapy. Am J Obstet Gynecol 1987 (156):1312–1322Google Scholar
  18. 18.
    Hillner BE, Hollenberg JP, Pauker SG: Postmenopausal estrogen in prevention of osteoporosis. Am J Med 1986 (80):1115–1127PubMedCrossRefGoogle Scholar
  19. 19.
    Henderson BE, Ross RK, Lobo RA, Pike MC, Mack TM: Re-evaluating the role of progestogen therapy after the menopause. Fert Steril 1988 (498 Suppl):9s–15sGoogle Scholar
  20. 20.
    Bergkvist L, Adami H-O, Persson I et al: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989 (321)293–297PubMedCrossRefGoogle Scholar
  21. 21.
    Jordan VC, Robinson SP: Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc 1987 (46):1870–1874PubMedGoogle Scholar
  22. 22.
    Harper MJK, Walpole AL: A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 1967 (13):101–119PubMedCrossRefGoogle Scholar
  23. 23.
    Broens J, Mouridsen HT, Soerensen HM: Tamoxifen in advanced endometrial carcinoma. Cancer Chemother Pharmacol 1980 (4):805–811CrossRefGoogle Scholar
  24. 24.
    Swenerton KD: Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 1980(64):805–811PubMedGoogle Scholar
  25. 25.
    Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving tamoxifen. Cancer Treat Rep 1985 (69):237–238PubMedGoogle Scholar
  26. 26.
    Hardell L: Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988 (ii):563CrossRefGoogle Scholar
  27. 27.
    Hardell L: Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet 1988 (il):1432CrossRefGoogle Scholar
  28. 28.
    Fornander T, Rutqvist LE, Cedermark B et al: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989 (l):117–120CrossRefGoogle Scholar
  29. 29.
    Satyaswaroop PG, Zaino RJ, Mortel R: Estrogen-like effect of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984 (44):4006–4010PubMedGoogle Scholar
  30. 30.
    Clark CL, Satyaswaroop PG: Photoaffinity labeling of the progesterone receptor from human endometrial carcinoma. Cancer Res 1985 (45):5417–5420Google Scholar
  31. 31.
    Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988 (48):812–815PubMedGoogle Scholar
  32. 32.
    Mouridsen HT, Ellemann K, Mattsson W et al: Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 1979 (63):171 -175PubMedGoogle Scholar
  33. 33.
    Jabara AG, Toyens PH, Harcourt AG: Effects of time and duration of progesterone administration on mammary tumors induced by 7,12-dimethylbenz(a)-anthracene in Sprague Dawley rats. Br J Cancer 1973(27):63–71PubMedCrossRefGoogle Scholar
  34. 34.
    Robinson SP, Jordan VC: Reversal of the antitumour effects of tamoxifen by progesterone in the 7, 12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 1987 (47):5386–5390PubMedGoogle Scholar
  35. 35.
    Robinson SP, Mauel DA, Jordan VC: Antitumour actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol 1988(24):1817–1821PubMedCrossRefGoogle Scholar
  36. 36.
    Gottardls MM, Jordan VC: Development of tamoxjfen-stimulated growth of MCF-7 tumors in athymlc mice after long-term antiestrogen administration. Cancer Res 1988 (48):5183–5187Google Scholar
  37. 37.
    Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antioestrogen therapy. Eur J Cancer Clin Oncol 1987 (23):1189–1196PubMedCrossRefGoogle Scholar
  38. 38.
    Gottardis MM, Wagner RJ, Borden EC, Jordan VC: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 1989 (49):4765–4769PubMedGoogle Scholar
  39. 39.
    Gottardis MM, Jiang SY, Jeng MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989 (49):4090–4093PubMedGoogle Scholar
  40. 40.
    Murray RML, Pitt P: Aminoglutethimide in tamoxifen-resistant patients: the Melbourne experience. Cancer Res 1982 (42 Suppl):3437s–3441sPubMedGoogle Scholar
  41. 41.
    Wakeling AE, Bowler J: Steroidal pure antioestrogens. J Endocrinol 1987 (112):R7–R10PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • V. Craig Jordan
    • 1
  1. 1.Department of Human OncologyUniversity of Wisconsin Clinical Cancer CenterMadisonUSA

Personalised recommendations